{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:45:12Z","timestamp":1759333512623},"reference-count":49,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T00:00:00Z","timestamp":1312416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Few reports exist on the use of biologics for treating patients with mild\u2010to\u2010moderate psoriasis, especially for non\u2010reimbursed patients.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> This study aimed to evaluate the safety and effectiveness of adalimumab in non\u2010reimbursed patients with mild\u2010to\u2010moderate psoriasis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Fifty one patients with mild\u2010to\u2010moderate psoriasis treated with adalimumab 40\u2003mg every other week (eow) in a tertiary referral hospital in Taiwan between 2007 and 2010 were retrospectively reviewed. The clinical effectiveness of adalimumab was assessed using Subject\u2019s Global assessment (SGA) and Physician\u2019s Global Assessment (PGA), and the reasons for discontinuation were evaluated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> After 12\u2003weeks of adalimumab (40\u2003mg subcutaneously eow without a loading dose) treatment, 66% and 74% of patients had SGA and PGA scores of at least marked improvement (greater than 50% improvement compared with baseline psoriasis), respectively, with 60% and 53% of patients achieving SGA and PGA scores of at least marked improvement after 24\u2003weeks. Ten (71%) of 14 previous non\u2010responders to etanercept achieved a SGA or PGA score of at least marked improvement after adalimumab treatment. Adalimumab was generally well tolerated, but four patients (7.8%) discontinued adalimumab due to adverse events. The mean time required for resumption of systemic anti\u2010psoriatic therapy was 6\u2003months (range, 1\u201312\u2003months). Apart from financial limitations, the most common reasons for discontinuation were primary (23.5%) and secondary (13.7%) lack of efficacy.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In non\u2010reimbursed mild\u2010to\u2010moderate psoriasis patients, SGA and PGA remained high for adalimumab. Effectiveness and remission duration were key factors affecting patients\u2019 willingness to pay for prolonged adalimumab treatment.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04199.x","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T14:32:18Z","timestamp":1312468338000},"page":"991-998","source":"Crossref","is-referenced-by-count":15,"title":["The effectiveness and safety of adalimumab in the treatment of non\u2010reimbursed patients with mild\u2010to\u2010moderate psoriasis"],"prefix":"10.1111","volume":"26","author":[{"given":"H.\u2010Y.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.\u2010S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.\u2010F.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02963.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0253"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00085.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0838"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06510.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.68"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09563.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.10.1403"},{"key":"e_1_2_5_16_2","article-title":"Concomitant occurrence of acne, alopecia areata, and urticarial eruption during treatment of adalimumab in a patient with pustulosispalmoplantaris: a case report and literature review","author":"He GY","journal-title":"Dermatologica Sinica"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10137.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08865.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09019.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03613.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09893.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03161.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.014"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03562.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04183.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7062.919"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083509"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03872.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.045"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.05.032"},{"key":"e_1_2_5_33_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1684\/ejd.2010.0815","article-title":"Concordance of the Psoriasis Area and Severity Index (PASI) and patient\u2010reported outcomes in psoriasis treatment","volume":"20","author":"Schafer I","year":"2010","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.106374"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2004.09115.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03325.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.11.009"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24463"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10139.x"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.18.2201-a"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.18.2202"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.18.2201-b"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"e_1_2_5_45_2","first-page":"167","article-title":"Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity","volume":"16","author":"van de Kerkhof PC","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01667.x"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629010-00004"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04660.x"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03207.x"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10213.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04199.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04199.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:06:09Z","timestamp":1697342769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04199.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04199.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04199.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,4]]}}}